<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>XELOX for unresectable advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> has been approved in Japan </plain></SENT>
<SENT sid="1" pm="."><plain>We report here an experience of the treatment with XELOX±bevacizumab in our department </plain></SENT>
<SENT sid="2" pm="."><plain>We thought that the regimen has some merits in the patient's quality of life </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-five patients were treated with XELOX±bevacizumab </plain></SENT>
<SENT sid="4" pm="."><plain>In evaluable 23 cases, partial response (PR) was obtained in 13 cases and stable disease (SD) and progressive disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) were in 5 and 5 cases, so that the response rate and disease control rate were 56.5% and 78.2%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>In the first-line administration of 19 cases, the response rate and disease control rate were respectively 80.0% and 90.0% </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">Hand-foot syndrome</z:e> was observed in 13.2% (grade 2) and 6 .6% (grade 3) </plain></SENT>
<SENT sid="7" pm="."><plain>We think that it is important to control <z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">hand-foot syndrome</z:e> for a continuation of XELOX±bevacizumab </plain></SENT>
</text></document>